Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Viatris Inc.NASDAQ: VTRS

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows in line with its trailing trend

Q2 FY2026 revenue of $3.76B rose 4.9% year over year, in line with the +4.4% change in trailing-twelve-month revenue. Sequentially, it rose 6.8% from the prior quarter. Over 3 fiscal years it compounded at -4.2% a year.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 7 analysts of $14.8B (+3.5%) for the fiscal year ending Dec 2026, a step up from the -3.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.76B+6.8% QoQ
Last fiscal yearDec 2025
$14.3B-3.0% YoY
LTMJun 2026
$14.74B+4.4% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.9%+0.7%-4.2 pp
1 year-3.0%+3.5%+6.5 pp
3-year CAGR-4.2%+3.6%+7.8 pp
5-year CAGR+3.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
14.3B USD
Year-over-year change
-3.0%
4-year CAGR
-5.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +4.4% is the 5th highest of 9, against a peer median of +6.7%.
  • Over three fiscal years its annual growth of -4.2% compares with a peer median of +9.9%.
VTRS Competitors
Revenue for VTRS and competitors
Company Period LTM YoY 3-year CAGR
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹331.38B INR-3.1%+12.9%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$17.31B USD+4.1%+5.0%
HLNHaleon plcLTM Jun 2025£16.54B GBP—+0.5%
VTRSViatris Inc.LTM Jun 2026$14.74B USD+4.4%-4.2%
BHCBausch Health Companies Inc.LTM Jun 2026$10.85B USD+10.1%+8.1%
OGNOrganon & Co.LTM Sep 2026$6.1B USD-3.2%+0.2%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$3.12B USD+9.3%+10.9%
ALKSAlkermes plcLTM Sep 2026$1.75B USD+15.3%+9.9%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$923.71M USD+37.0%+40.8%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$720.53M USD-1.1%+13.0%
Peer median (excluding VTRS) —+6.7%+9.9%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.89B16.26B15.43B14.74B14.3B
Cost of Revenue12.31B9.77B8.99B9.12B9.29B
Gross Profit5.58B6.5B6.44B5.62B5.01B
Gross Margin31.2%40.0%41.7%38.2%35.1%
Research & Development681M662.2M805.2M808.7M965.9M
Selling, General & Admin4.53B4.18B4.65B4.43B3.79B
Operating Expenses5.61B4.88B5.67B5.61B7.68B
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
EBITDA4.48B6.43B3.52B2.64B(395.4M)
EBITDA Margin25.0%39.6%22.8%17.9%-2.8%
Operating Income(34M)1.61B766.2M10.1M(2.66B)
Operating Margin-0.2%9.9%5.0%0.1%-18.6%
Interest Income00000
Interest Expense636.2M592.4M573.1M550M471.3M
Other Income / Expenses(630.4M)1.2B(563.3M)(633.3M)(1B)
Income Before Tax(664.4M)2.81B202.9M(623.2M)(3.67B)
Pre-Tax Margin-3.7%17.3%1.3%-4.2%-25.6%
Income Tax Expense604.7M734.6M148.2M11M(150.1M)
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Net Margin-7.1%12.8%0.4%-4.3%-24.6%
EPS (Basic)(1.05)1.710.05(0.53)(3.00)
EPS (Diluted)(1.05)1.710.05(0.53)(3.00)
Weighted Avg Shares1.21B1.21B1.2B1.19B1.17B
Weighted Avg Shares (Diluted)1.21B1.22B1.21B1.19B1.17B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.